Scancell Holdings Plc. said a patent for its DNA ImmunoBody technology has now been granted in Europe.
The platform was used to develop SCIB1 and SCIB2 – the company’s leading drug candidates. The two are designed to help the body’s immune system to fight cancer.
“The addition of this key European patent for DNA ImmunoBody significantly bolsters our global intellectual property portfolio as we position the company for future growth,” said chief executive Richard Goodfellow.
Scancell already has patent protection in the United States, Australia and Japan.
Disclaimer: The opinions expressed by our writers are their own and do not represent the views of Scommerce. The information provided on Scommerce is intended for informational purposes only. Scommerce is not liable for any financial losses incurred. Conduct your own research by contacting financial experts before making any investment decisions.